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An update on vitamin D as related to nephrology practice:
2003. In this article, an up-to-date consideration of vitamin D
therapeutics in nephrology is reviewed. The condition of vita-
min D insufficiency is defined as the level of serum 25(OH)-
vitamin D at which vitamin D2 or D3 supplementation leads to
a reduction of levels of parathyroid hormone (PTH). The risks
of such vitamin D insufficiency in the normal population and
likely risks in individuals with chronic kidney disease (CKD)
stages 3 and 4 are reviewed. The potential for its safe treatment
and prevention using moderate supplements of vitamin D2 or
vitamin D3 are outlined. The role of altered “vitamin D nutri-
tion” in leading to the observed greater incidence of secondary
hyperparathyroidism in African Americans with ESRD com-
pared to other racial groups is considered. The actions of active
vitamin D sterols to augment intestinal absorption of both
calcium and phosphorus, the effect to reduce levels of PTH,
and to be a factor contributing to the rising incidence of low
bone turnover (adynamic bone) are discussed. Growing evi-
dence for contributions of elevated levels of serum calcium,
serum phosphorus, and the calcium  phosphorus product
as factors contributing to vascular and cardiac calcification in
ESRD patients are cited. Questions are raised about whether
the current practice of vitamin D usage in ESRD patients might
be a contributing factor to such vascular abnormalities. The
economic factors that likely affect the usage of intravenous
vitamin D sterols in the United States are reviewed. It is recom-
mended that potential adverse vascular effects of vitamin D
sterols related to the increments of serum Ca and P be carefully
evaluated.
This review focuses on several aspects of the clinical
use of vitamin D sterols, which include: (1) the recent
data regarding vitamin D nutrition as a factor leading
to osteoporosis and the potential role of impaired vita-
min D nutrition in patients with chronic kidney disease
(CKD); (2) the clinical actions of the active vitamin D
sterols, including the newer active analogs of calcitriol
used in the management of secondary hyperparathyroid-
ism in ESRD; (3) the economic factors that may affect
vitamin D usage in the United States; and (4) a consider-
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ation of clinical practices of vitamin D usage that could,
indeed, be harmful.
The data derived from study of the elderly and of those
with osteoporosis have provided important implications
regarding patients with kidney disease. The changes of
vitamin D metabolism during the development of vita-
min D deficiency, as studied in dogs fed a low calcium and
vitamin D-deficient diet for two years [1], are pertinent.
Serum iPTH levels rose within days with accompanying
hypophosphatemia; however, serum 1,25-dihydroxyvita-
min D (calcitriol) levels rose even as 25-hydroxyvita-
min D levels fell. These adaptations maintained normal
ionized Ca levels for 6 months. Subsequently, hypocal-
cemia appeared, 1,25(OH)2D levels fell (although remain-
ing within the normal range), and 25(OH)D levels de-
creased further to very low levels. Thus, the serum level
of 25-hydroxyvitamin D, not the level of 1,25-dihydroxy-
vitamin D, provides an indication of the body stores of
vitamin D. 25-Hydroxyvitamin D, which circulates at a
concentration 1000-fold higher than that of 1,25-dihydroxy-
vitamin D or calcitriol, has a plasma half-life of 25 to 30
days, and the measurement of 25(OH)D levels provides
a means to detect vitamin D deficiency or insufficiency,
even in those with kidney disease [2, 3]. The measure-
ment of plasma 1,25(OH)2D levels can be useful to iden-
tify unusual causes of hypercalcemia or hyperphosphate-
mia, but its measurement provides no indication of
nutritional vitamin D-deficiency [4]. The maintenance
of normal or even elevated serum levels of 1,25(OH)2D
in severe secondary hyperparathyroidism due to vitamin
D-deficiency occurs because of the highly efficient con-
version of 25(OH)D to 1,25(OH)2D, even when the con-
centration of the former is markedly reduced [5].
A modest reduction in the serum level of 25(OH)D,
the substrate for the generation of 1,25(OH)2D, leads
to mild secondary hyperparathyroidism in those with
normal kidney function [6, 7] and may aggravate second-
ary hyperparathyroidism in those with chronic kidney
disease and reduced renal function [8, 9]. True vitamin D
deficiency, with hypocalcemia and osteomalacia, is rare
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Fig. 1. Changes from baseline of serum calcium levels during therapy
with either paricalcitol (solid bars) or intravenous doxercalciferol (cross-
hatched bar) observed in controlled trials that employed only calcium-
based phosphate-binding agents. The data are mean  SE when such
information can be calculated or shown without an “error” bar when
variance of the data was not provided. “No.” indicates the number of
subjects receiving the sterol in the trial.
in the United States; it is associated with 25(OH)D levels
below 5 to 7 ng/mL. However, levels of 25(OH)D from
7 to 30 ng/mL, which are within the “reference range”
of 7 to 80 ng/mL, are indications of vitamin D insuffi-
ciency. The latter is recognized because modest supple-
ments of vitamin D2 or D3 can lower serum iPTH levels
[10, 11]. Patients over 60 years of age with hip fractures
have lower 25(OH)D levels than age-matched individu-
als with no fracture, and “normal” elderly subjects with
25(OH)D levels 30 ng/mL have lower bone mineral
density than those with higher levels [12, 13]. The only
disagreement is the upper value of serum 25(OH)D level
at which one does not encounter significant numbers
of patients with mild elevations of serum iPTH levels,
indicating that 25(OH)D levels should be maintained at
higher levels. Evidence for the importance and frequency
of vitamin D-insufficiency is indicated by results of pla-
cebo-controlled prospective studies in New England [14],
Europe [15], and the United Kingdom [16] that demon-
strated significant reductions in fracture incidence in
individuals over 60 to 65 years given supplements of
vitamin D3 or D2, 600 to 800 units/day. Thus, vitamin D
insufficiency is characterized clinically by mild secondary
hyperparathyroidism, osteoporosis, and increased risk of
fracture.
Concerning patients with kidney disease, one study of
Fig. 2. The percentage of all serum calcium measurements that ex-
ceeded various limits is shown on the horizontal axis in two trials using
either paricalcitol or intravenous doxercalciferol. For some of the limits,
the data were not available. For clarity, the percentage is shown in a
log10 scale. N is the total number of measurements.
63 non-nephrotic patients with varying levels of renal
function found median values of 25(OH)D to be 12, 19,
and 18 ng/mL in subgroups with glomerular filtration rate
(GFR) estimated to be 60 to 90 mL/min, 40 to 60 mL/
min, and 20 to 40 mL/min, respectively [17]. Most had
25(OH)D values below 30 ng/mL and many had levels
below 15 ng/mL [17]. In another study of 76 CKD pa-
tients, 37 with diabetic kidney disease and 39 CKD from
other causes [18], the 25(OH)D level averaged 22  9.4
in the nondiabetic group and 11  5.6 pg/mL in the
diabetic patients. The serum albumin levels were lower
in the diabetics and 76% had urinary protein concentra-
tions above 300 mg/dL compared to only 23% of the
nondiabetic group. In another study that included 27
patients with GFR of 30 to 70 mL, 79% of patients had
25(OH)D levels below 30 ng/mL and the levels were
below 16 ng/mL in 18% [19]. In a United States study
of 20 patients with GFR of 18 to 70 mL/min, the mean
25(OH)D levels were 12 ng/mL in those with nephrotic
syndrome, and 20 ng/mL in those lacking nephrotic pro-
teinuria. Most subjects in both groups obviously had
suboptimal levels of 25(OH)D. In a United States study
of medical inpatients, with exclusion of those undergoing
dialysis, the presence of impaired renal function was a
risk factor for the finding of low levels of 25(OH)D [11].
In the two largest series of CKD patients noted above,
there were significantly positive correlations between the
levels of 1,25(OH)2D and those of 25(OH)D, with r 
0.51 [20] and r  0.47 [18]. These observations differ
from findings in normal individuals, including those with
vitamin D deficiency [5], in whom 1,25(OH)2D levels are
not dependent on the 25(OH)D levels, even in those
with low levels of 25(OH)D [5]. The normal highly effi-
cient renal production of 1,25(OH)2D may be altered in
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CKD, stages 3 and 4, when the supply of 25(OH)D is
reduced. Thus, the levels of 1,25(OH)2D may be depen-
dent on the availability of its substrate, 25(OH)D, in
patients with CKD, stages 3 and 4 [4], and in those with
ESRD [21].
Because of the higher frequency of secondary hyper-
parathyroidism in African Americans compared to whites
both with ESRD [22] and with mild to moderate renal
insufficiency [23], a consideration of vitamin D nutrition
in African Americans is pertinent; this is reviewed in
detail elsewhere [24]. In normal African Americans liv-
ing in temperate climates of Europe and the United
States, the impaired dermal synthesis of vitamin D likely
results in 25(OH)D levels that are about 50% lower than
those in whites; the concomitant findings that iPTH levels
are slightly higher and 1,25(OH)D levels are increased
are not surprising. These biochemical features are totally
reversed by the administration of either vitamin D or
25(OH)D. When black African individuals moved from
the Congo to Belgium, there was a fall of mean 25(OH)D
levels from 50 to 9 ng/mL over two years, a finding that
indicated that sun exposure at latitudes near the equator
led to adequate vitamin D synthesis. It is known that
bone biopsies in healthy African Americans show ero-
sion surfaces that are about 50% lower than in whites
[25], indicating there is altered skeletal responsiveness
to PTH for reasons that are uncertain. It is well known
that bone density is higher in normal African Americans
than whites, with similar findings in ESRD. Moreover,
African Americans with ESRD and of either gender
have a reduced risk of fracture [26]. Nonetheless, pro-
gressive secondary hyperparathyroidism is common in
African Americans as the duration of dialysis increases.
It is a proposed recommendation of the Kidney Dial-
ysis Outcomes Quality Initiative (K-DOQI) Work
Group that serum 25(OH)D level be measured in pa-
tients with CKD, stages 3 and 4, with elevations of iPTH
above certain limits. If the 25(OH)D levels are below
30 ng/mL, replacement with vitamin D is recommended.
Because of its pharmaceutical availability, the most con-
venient method in the United States is the monthly ad-
ministration of ergocalciferol (vitamin D2), 50,000 IU
each month. From a safety standpoint, this monthly dose
is less than the upper limit of daily dosage of 2000 IU/
day recommended by the Food and Nutrition Board,
National Research Council, and National Academy of
Sciences. Treatment of overt vitamin D deficiency with
evidence of osteomalacia and severe secondary hyper-
parathyroidism requires larger doses. A parenteral form
of ergocalciferol, with 500,000 IU per mL, is available
for intramuscular administration. It has been suggested
that the administration of one single large intramuscular
treatment may be curative for vitamin D deficiency [27],
avoiding the problem with compliance, particularly in
developing countries where either limited access to care
and/or cultural differences or customs leads to poor com-
pliance and treatment failure [28]. The sterol 25(OH)D3,
or calcifediol, has been available for 20 years; there may
be a small pharmaceutical advantage of using calcifediol
rather than calciferol or ergocalciferol to treat vita-
min D deficiency since calcifediol is available in 20 and
50g capsules (Calderol, Organon). However, this prod-
uct may not be readily available, and the added cost may
not justify its use. For the prevention or treatment of
vitamin D deficiency or insufficiency as defined by
25(OH)D levels, there is no place for the use of calcitriol,
alfacalcidol, or any of the newer active vitamin D analogs.
ACTIVE VITAMIN D STEROLS IN ESRD
In conjunction with phosphate-binding agents, the
active vitamin D sterols, calcitriol and alfacalcidol
(1(OH)D3), have been utilized for more than 20 years,
with intravenous forms in wide use for 10 years, particu-
larly in the United States. The known actions of calcitriol
include augmentation of intestinal absorption of both
calcium and phosphorus [29], with a tendency for serum
Ca and P to rise when kidney function is reduced. Be-
cause of calcitriol’s indirect effect to raise serum Ca level
and its direct action to reduce the synthesis of mRNA
for pre- pro-PTH in the parathyroid gland, there is re-
duced PTH secretion. There are no conclusive data that
treatment with calcitriol or alfacalcidol has any effect to
reverse pre-existing parathyroid hyperplasia.
With the use of intravenous “pulse” therapy, bone
turnover is reduced and this is the dominant effect on
bone. During intravenous calcitriol therapy, the degree
of reduction of bone formation rate (BFR) seems to be
greater than the reduction of PTH levels. This reduced
BFR arises due to a reduction of the length of double
label, with the apposition rate, or distance between the
double labels, remaining unchanged [30]. This indicates
that a major effect of pulse calcitriol on bone is to dimin-
ish the number of active osteoblasts. In studies in chil-
dren and adolescents, pulse calcitriol therapy has been
shown to lead to the appearance of adynamic bone [31]
and, in pre-pubertal children with ESRD, to reduce the
rate of linear growth [32]. There is indirect evidence
that pulse therapy with calcitriol, combined with the
widespread use of calcium-based phosphate-binding
agents, contributes to the increased prevalence of ady-
namic bone. Another change over the last decade has
been a change in the relationship between bone turnover
rate, as determined from bone biopsy, and the levels of
intact PTH. In studies of ESRD patients undergoing
biopsies between 1985 and 1990, correlations between
BFR and iPTH were reasonably good as long as alumi-
num-induced bone disease was excluded [33, 34]. In a
more recent biopsy series that included some patients
who received pulse vitamin D therapy for varying peri-
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ods, very poor correlations between iPTH levels and
bone turnover were found. Indeed, the level of iPTH
did not distinguish between adynamic bone from bone
having normal or high turnover when the iPTH levels
ranged from 200 to 600 pg/mL [35].
During the last five years, two new vitamin D sterols
have been introduced in Japan and two in the United
States. For two sterols, 22-oxa-calcitriol (maxicalcitol)
and paricalcitol (1,25(OH)2-19-nor-vitamin D2), there
are studies in experimental animals showing little or no
augmentation of intestinal calcium absorption, while
there were potent actions to suppress PTH levels inde-
pendent of increments in serum Ca [36, 37]. The present
discussion will be limited to paricalcitol and doxercalcif-
erol, two newer sterols used in the United States. Doxer-
calciferol (1(OH)D2), like alfacalcidol, is a prohormone
that is 25-hydroxylated in the liver before inducing its
actions. In vitamin D deficiency animals, doxercalciferol
and alfacalcidol are equally potent in curing rickets; how-
ever, when given in larger doses, doxercalciferol had far
less calcemic action [38]. In an animal model of osteopo-
rosis produced by ovariectomy, doxercalciferol protected
against bone loss without increasing urinary Ca, while
the other sterols tested, including 1(OH)D3, caused sub-
stantial hypercalciuria when given in doses that protected
against bone loss [39]. In osteoporotic women, the ad-
ministration of doxercalciferol in doses up to 5 g/day
did not produce hypercalciuria [40], while much smaller
doses of (1(OH)D3) produced significant hypercalciuria
[41].
The clinical data analyzed for the effects of paricalcitol
and doxercalciferol are limited to reports of prospective
studies in comparison to placebo [42–45]. For paricalcitol
compared to calcitriol, a large blinded comparison of
intravenous paricalcitol to intravenous calcitriol has
been reported. In all of these trials, only calcium-based
phosphate-binding agents were employed. Both parical-
citol [42] and doxercalciferol [46] were highly effective
in lowering iPTH levels, although the trials with oral
doxercalciferol included a substantial fraction with iPTH
levels above 1200 pg/mL [47].
Clinical trials with both paricalcitol and doxercalcif-
erol showed modest increments in both serum calcium
and phosphorus, and there are no studies with either
sterol, such as have been reported with calcitriol, that
measured intestinal absorption of calcium and phospho-
rus using either balance techniques or radiolabeled cal-
cium. The observation that hypercalcemia was more
likely to occur in trials with paricalcitol when the serum
iPTH levels were reduced below 100 pg/mL suggests that
such patients likely had oversuppression of PTH with
adynamic bone [48], with the lack of bone buffering, as
has been documented in patients with biopsy demonstra-
tion of adynamic bone [49]. Since all the studies cited
for comparison employed only calcium-based phosphate-
binding agents, any effect of the sterol to augment intesti-
nal absorption would be amplified by the high calcium
intake.
In this comparison of the effects of these sterols to
raise serum calcium, there are five controlled studies
using paricalcitol [42, 43, 44, 45] with data that permit
the determination of the relative increase of serum cal-
cium, and one trial with intravenous doxercalciferol [46]
(Fig. 1). With paricalcitol, the rise of serum calcium was
3% to 4% in three trials [42, 43], while the rise was
greater in two studies with far fewer patients in the stud-
ies [44, 45]. In the trial using intravenous doxercalciferol,
the increment of calcium averaged 4% at eight weeks
of therapy [46]. In two trials reporting data on the frac-
tions of serum calcium measurements that exceeded lev-
els from 10.5 to 12.0 mg/dL, no differences could be
seen between the two sterols (Fig. 2). The mean incre-
ments of serum phosphorus (data not shown) varied
from 6.6 to 12.6% in three trials using paricalcitol [42, 43]
and were 10.1% in the trial using doxercalciferol [46].
Although not direct comparisons, such data suggest there
is little difference between the sterols with regard to their
effect to raise the levels of serum calcium or phosphorus.
The large double-blind trial that compared intrave-
nous paricalcitol with intravenous calcitriol [50] is nota-
ble. With intravenous paricalcitol, iPTH levels fell more
rapidly than was observed in the group receiving intrave-
nous calcitriol, possibly related to a ratio of dosing of
4:1 for paricalcitol:calcitriol. The fraction of patients
showing a lowering of iPTH by 50% was 62% with
paricalcitol and 54% with calcitriol (P  NS). With re-
gard to side effects, 68% of the calcitriol group and 64%
of the paricalcitol group had at least one episode of
hypercalcemia (corrected calcium 11.5 mg/dL) or a
Ca  P product 75 (P  NS). However, in the assess-
ment of more prolonged side effects, defined as two
successive serum calcium levels 11.5 mg/dL or four
successive elevations of the serum Ca  P product 75
(with serum calcium and phosphorus measured twice
weekly), the results favored paricalcitol; thus, 18% of
paricalcitol patients compared to 33% of the calcitriol
group fulfilled these criteria (P 0.01). Neither the over-
all incidence of hyperphosphatemia nor the percentage
increments of serum calcium or phosphorus were re-
ported, but inspection of graphic data, provided by Dr.
S. Sprague, revealed significant increments in both treat-
ment groups. Nonetheless, this large study suggests there
may be some benefit of paricalcitol over calcitriol, with
both given intravenously. A recent report of a retrospec-
tive analysis indicates that the mortality of ESRD pa-
tients who initiated therapy with intravenous calcitriol
was higher than the mortality of patients given paricalci-
tol initially [51]. However, the assignment of patients to
one sterol or the other was not random, and it is possible
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that factors other than the type of vitamin D sterol con-
tributed to the difference.
CONCLUSION
This review will conclude with a brief consideration of
factors affecting the administration and dosing of these
vitamin D sterols and consider the possibility of deleteri-
ous effects. The initial demonstration [52], and then con-
firmation that hyperphosphatemia [53–55] and oral cal-
cium loading [56] may contribute to vascular and cardiac
calcifications and to increased mortality in ESRD pa-
tients, alters the importance of controlling mineral me-
tabolism in ESRD patients. These data causes us to ask,
“Does our current usage of vitamin D contribute in any
way to the high mortality in ESRD patients?” Might the
potential clinical benefits of lowering of PTH be offset
by detrimental effects caused by increasing the serum
levels of calcium or phosphorus or of both? The preva-
lence of calciphylaxis (uremic calcific arteriolopathy),
which had largely vanished 20 to 25 years ago, seems
to have risen over the past 10 to 15 years. Could the
administration of pulse doses of calcitriol or other vita-
min D sterols contribute to a presumed higher incidence
of this syndrome? Unfortunately, a diagnosis of calciphy-
laxis does not appear in ICD9 codes, so its prevalence
is difficult to document. As anecdotal experience, I am
unaware of any de novo cases of calciphylaxis appearing
in three dialysis centers that I visit, and the fraction of
patients receiving intravenous vitamin D, when assessed
in the past, was only 40% to 45%. Regarding the preva-
lence of vitamin D usage in centers describing multiple
cases of calciphylaxis, the use of vitamin D use was stated
to be either universal or a much higher percentage. In
the United States, the profit arising from the reimburse-
ment for administration of intravenous drugs, such as
erythropoietin or intravenous vitamin D sterols, during
hemodialysis may separate a unit showing a “profit” from
another with problems meeting its costs. The report indi-
cating there may be an excess death rate with use of
intravenous calcitriol must raise a question about the
appropriateness of current vitamin D usage in the United
States. If increments in the serum phosphorus, serum
calcium, or the calcium phosphorus product contribute
to cardiovascular mortality, it would seem likely that
increments associated with use of active vitamin D ste-
rols may also exert the same detrimental effect. Further
careful study of such potential side effects of our therapy
seems both appropriate and essential.
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